SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
GAN Limited (GAN) .
Criteria proven by this page:
- VALUE (0/100, Fail) — the composite valuation score falls below the 60/100 threshold required to pass.
Overall SharesGrow Score: 27/100 with 0/7 criteria passed.
SharesGrow 7-Criteria Score
~
HEALTH
50/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — GAN
Valuation Multiples
P/E (TTM)0.0
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio0.66
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-0.18
Book Value / Share$0.00
Revenue / Share$2.97
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2015 |
$-0.13 |
$8.86M |
$-7.41M |
-83.5% |
| 2016 |
$-0.07 |
$9.62M |
$-4.63M |
-48.2% |
| 2017 |
$-0.07 |
$12.31M |
$-4.7M |
-38.1% |
| 2018 |
$-0.39 |
$14.02M |
$-7.7M |
-54.9% |
| 2019 |
$0.09 |
$29.97M |
$1.79M |
6% |
| 2020 |
$-0.75 |
$35.16M |
$-20.22M |
-57.5% |
| 2021 |
$-0.59 |
$125.43M |
$-24.9M |
-19.9% |
| 2022 |
$-4.66 |
$141.53M |
$-197.5M |
-139.5% |
| 2023 |
$-0.78 |
$129.42M |
$-34.44M |
-26.6% |
| 2024 |
$-0.18 |
$135M |
$-7.96M |
-5.9% |
